OmarAlhalabiMD

Assistant Professor

Dr. Alhalabi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Omar Alhalabi, based in Houston, Texas, specializes in Oncology. He received his medical degree from Damascus University Faculty of Medicine in 2013, completed his residency in Internal Medicine at Beaumont Health (Royal Oak) from 2014-2017, and pursued a fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/M D Anderson Cancer Center from 2017-2020. He has publications in various reputed journals including The Oncologist, the Journal of Urology, the European Urology Oncology, and Journal of Clinical Oncology. Additionally, Dr. Alhalabi is involved in clinical trials, including a Phase 2 study evaluating the triplet combination of Pemetrexed Plus AB928 + AB122 in patients with advanced or metastatic MTAP Deficient Urothelial Carcinoma, and a Phase 1a/b study of IK-175 combined with Nivolumab in patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma.

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 2014 - 2017
Damascus University Faculty of MedicineClass of 2013, MD

PubMed

Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review.
Emanuele Crupi, Tiago Costa de Padua, Laura Marandino, Giuseppe Fallara, Filippo Pederzoli
JCO Precision Oncology. 2024-12-01
Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.
Patrick Carriere, Omar Alhalabi, Jianjun Gao, Osama Mohamad, Matthew T Campbell
Clinical and Translational Radiation Oncology. 2024-11-01
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy.
Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, Sagar A Naik, Vivek Subbiah
Current Oncology. 2024-06-13

Lectures

Correlation of methylthioadenosine phosphorylase (MTAP) loss with response to anti-folate therapy in urothelial bladder carcinoma (UBC).
2019 ASCO Annual Meeting - 6/1/2019

Metastatic Prostate Cancer: Investigators Ponder New Path to Improve SurvivalSeptember 30th, 2022
Noncancer Causes of Death ‘Increasingly Pertinent’ Among Men with Advanced Prostate CancerOctober 29th, 2021
Old Saying About Prostate Cancer Not True When It’s MetastaticSeptember 7th, 2021
Join now to see all